Blood Test Study for Finding Liver Cancer in Adults
Tests a blood sample method for detecting liver cancer in adults aged 18 to 75.
Plain-language title generated from the registry record
Registry title: Hepatocellular Carcinoma Identification Using Delta-HLD
Key facts
- Where
- Mendoza, ArgentinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07148310, who can take part
Where in Argentina
- EpiliquidMendoza, ArgentinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Epiliquid Holding, Inc
- Trial code
- NCT07148310
- Record updated
- 9 September 2025
- Original description
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.Read full original descriptionShow less
Proof-of-Concept Case-Control Study for Hepatocellular Carcinoma Identification Using Delta-HLD Technology (HIDE)
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.
Inclusion: Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls); Willing and able to provide informed consent; Available paired plasma and liver tissue sample.
Exclusion: Prior liver transplantation; Recent chemotherapy or antiviral treatment (<3 months); Other active cancers; Known hereditary cancer syndromes.